AbCellera Biologics Inc.
ABCL stock score: 52/100
$12.24 · +4.53% · Scored Oct 21, 2026
- Technical
- 67
- Fundamental
- 38
- News
- —
The reading
AbCellera Biologics (ABCL) scores 52 out of 100, which reads neutral, higher than 67% of Healthcare stocks and 48% of the 4,166 US stocks we score.
The composite is technicals and fundamentals weighted equally: technicals read 67, fundamentals 38.
Among the fundamentals, Quick Ratio at 100 and Current Ratio at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 48 and contrarian oscillators 61.
Since Jul 25, 2026 the composite has ranged from 49 to 70, and it is up 3 points over the period.
What’s driving the score
The strongest and weakest of the scorers that count toward ABCL’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
38Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Current Ratio100
Current ratio measures ability to pay short-term liabilities with current assets.
- Fund Ownership100
Fund ownership tracks institutional investor holdings and changes.
Holding it back
- Earnings Profitability (Quarterly)0
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
- Earnings Quality (Annual)0
Earnings Quality (Annual) assesses absolute profitability independent of growth, measuring whether the company is profitable, its earnings yield (earnings/market cap), profit margins, and consistency.
- EV/Revenue0
EV/Revenue compares the whole company's value, debt included, with its sales.
39 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
56Pulling it up
- Money Flow Index (14)100
Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.
- EMA 200100
Exponential Moving Average (200-period) is a crucial long-term trend indicator that reacts faster than SMA-200.
- SMA 200100
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Holding it back
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
- Parabolic SAR (PSAR)0
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- SMA 20 Cross Up6
SMA 20 Cross Up tracks when very short-term averages cross above the 20-period SMA.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 56 | 1 |
| Daily | 56 | 3 |
| Weekly | 72 | 2 |
| Monthly | 75 | 2 |
| Quarterly | 74 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Oct 21, 2026 | 52 |
| Oct 20, 2026 | 51 |
| Oct 19, 2026 | 50 |
| Oct 18, 2026 | 50 |
| Oct 17, 2026 | 50 |
| Oct 16, 2026 | 50 |
| Oct 15, 2026 | 52 |
| Oct 14, 2026 | 51 |
| Oct 13, 2026 | 52 |
| Oct 12, 2026 | 52 |
| Oct 11, 2026 | 52 |
| Oct 10, 2026 | 52 |
| Oct 9, 2026 | 52 |
| Oct 8, 2026 | 51 |
| Oct 7, 2026 | 52 |
| Oct 6, 2026 | 53 |
| Oct 5, 2026 | 54 |
| Oct 4, 2026 | 53 |
| Oct 3, 2026 | 53 |
| Oct 2, 2026 | 53 |
| Oct 1, 2026 | 53 |
| Sep 30, 2026 | 54 |
| Sep 29, 2026 | 56 |
| Sep 28, 2026 | 55 |
| Sep 27, 2026 | 55 |
| Sep 26, 2026 | 55 |
| Sep 25, 2026 | 55 |
| Sep 24, 2026 | 55 |
| Sep 23, 2026 | 55 |
| Sep 22, 2026 | 55 |
| Sep 21, 2026 | 55 |
| Sep 20, 2026 | 55 |
| Sep 19, 2026 | 55 |
| Sep 18, 2026 | 55 |
| Sep 17, 2026 | 55 |
| Sep 16, 2026 | 55 |
| Sep 15, 2026 | 54 |
| Sep 14, 2026 | 53 |
| Sep 13, 2026 | 53 |
| Sep 12, 2026 | 53 |
| Sep 11, 2026 | 52 |
| Sep 10, 2026 | 51 |
| Sep 9, 2026 | 52 |
| Sep 8, 2026 | 55 |
| Sep 7, 2026 | 55 |
| Sep 6, 2026 | 55 |
| Sep 5, 2026 | 55 |
| Sep 4, 2026 | 54 |
| Sep 3, 2026 | 55 |
| Sep 2, 2026 | 54 |
| Sep 1, 2026 | 53 |
| Aug 31, 2026 | 53 |
| Aug 30, 2026 | 53 |
| Aug 29, 2026 | 53 |
| Aug 28, 2026 | 53 |
| Aug 27, 2026 | 55 |
| Aug 26, 2026 | 55 |
| Aug 25, 2026 | 56 |
| Aug 24, 2026 | 53 |
| Aug 23, 2026 | 54 |
| Aug 22, 2026 | 54 |
| Aug 20, 2026 | 55 |
| Aug 19, 2026 | 56 |
| Aug 18, 2026 | 56 |
| Aug 17, 2026 | 56 |
| Aug 16, 2026 | 57 |
| Aug 15, 2026 | 56 |
| Aug 14, 2026 | 57 |
| Aug 13, 2026 | 57 |
| Aug 12, 2026 | 57 |
| Aug 11, 2026 | 56 |
| Aug 10, 2026 | 56 |
| Aug 9, 2026 | 55 |
| Aug 8, 2026 | 55 |
| Aug 7, 2026 | 55 |
| Aug 6, 2026 | 54 |
| Aug 5, 2026 | 52 |
| Aug 3, 2026 | 52 |
| Aug 2, 2026 | 51 |
| Jul 31, 2026 | 70 |
| Jul 30, 2026 | 68 |
| Jul 29, 2026 | 67 |
| Jul 28, 2026 | 50 |
| Jul 27, 2026 | 49 |
| Jul 26, 2026 | 49 |
| Jul 25, 2026 | 49 |
Key facts
- Market cap
- $4.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.41
- Risk grade (1–10)
- 6
- Next earnings
- Nov 9, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| DNTH Dianthus Therapeutics | $4.4B | 45 |
| EWTX Edgewise Therapeutics | $4.3B | 46 |
| RLAY Relay Therapeutics | $4.0B | 50 |
| ARQT Arcutis Biotherapeutics | $4.0B | 61 |
| LEGN Legend Biotech | $3.6B | 41 |
| XENE Xenon Pharmaceuticals | $3.5B | 36 |
Questions
What is ABCL's stock score today?
ABCL scores 52/100 (Neutral) as of Oct 21, 2026: technical 67, fundamental 38. Scores are recomputed every night.
Is ABCL a buy?
The score is not a buy or sell recommendation. A 52 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ABCL score calculated?
101 weighted scorers feed it today: 39 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.